LANSING, Mich., May 30, 2023 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 43rd Annual William Blair Growth Stock Conference in Chicago, Illinois, on Tuesday, June 6, 2023.
John Adent, Neogen's President and Chief Executive Officer, will present at 4:00 p.m. Central Time.
Presentation materials will be posted to the Neogen Investor Relations website on the morning of June 6. To access them, along with the event webcast link, please visit the Events & Presentations section at neogen.com/investor-relations/events-presentations.
About Neogen
Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "Every day, protect the people and animals we care about." The Company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.
CONTACT: | Bill Waelke, Investor Relations |
517.372.9200, This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$14.90 |
Daily Change: | -0.19 -1.26 |
Daily Volume: | 1,184,755 |
Market Cap: | US$3.230B |
October 10, 2024 July 30, 2024 June 27, 2024 April 09, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB